HomeNews

News

  • New Drug Candidate identified for Parkinson’s Disease

    • September 5, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Esbriet dose modifications do not alter treatment effect in IPF, study finds

    • August 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Phase 1b data for alzheimer’s disease treatment aducanumab announced

    • August 29, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Preclinical Study Results presented for IPF drug BBT-877, by Bridge Biotherapeutics

    • August 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • New form of Multiple Sclerosis, MCMS, identified by investigators

    • August 23, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Multiple Sclerosis patients taking IV treatment mostly satisfied, claims study

    • August 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Increased Anxiety & Depression in Higher frequency Migraine patients, new research study says

    • August 20, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA Approves ORKAMBI in Cystic Fibrosis for Children Ages 2-5 Years

    • August 13, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA approved new ADHD drug JORNAY PM

    • August 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • TG Therapeutics completes Enrollment for Ublituximab in MS trial

    • August 12, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more